Index Rebalance and Special Situations, Quiddity Advisors

Afridi Reyal

Index Rebalance and Special Situations

Quiddity Advisors

Pan-Asia Catalysts/Events

Index Rebalance

Jpmorgan Claverhouse It / Index Rebalance

<ul>
<li>In this insight, we take a look at the potential index changes for the F100 and F250 in the run-up to the March 2026 index rebal event.</li>
<li>We see two M&amp;A-related intra-review changes for the F250 index prior to the March 2026 rebal. Both are likely to happen in the next two weeks.</li>
<li>Our latest estimates suggest there could be <em>no</em> regular changes for the F100 and F250 indexes during the March 2026 rebal which follows.</li>
</ul>


In this insight, we take a look at the potential index changes for the F100 and F250 in the run-up to the March 2026 index rebal event.
We see two M&amp;A-related intra-review changes for the F250 index prior to the March 2026 rebal. Both are likely to happen in the next two weeks.
Our latest estimates suggest there could be no regular changes for the F100 and F250 indexes during the March 2026 rebal which follows.


Quiddity Leaderboard F100/F250 Mar26: Two High-Impact Intra-Review ADDs

IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Event-Driven

<ul>
<li>The <a href="https://www.smartkarma.com/entities/probiotec-ltd" target="_blank" data-smartkarma-citation="entities:12047:1" rel="noopener">Probiotec Ltd (PBP AU)</a> IE considers <a href="https://www.smartkarma.com/entities/pyridam-farma-tbk-pt" target="_blank" data-smartkarma-citation="entities:12900:1" rel="noopener">Pyridam Farma (PYFA IJ)</a>’s A$3.00 offer fair and reasonable as it is within its A$2.79-A$3.28 per share valuation range.</li>
<li>The scheme remains conditional on shareholders' (Probiotec and Pyridam), FIRB, and OJK approvals. Probiotec can also pay a permitted dividend of up to A$0.04 per share.</li>
<li>The gross spread of 4.9% (6.3% including dividends) reflects doubts about Pyridam’s funding credibility, as Pyridam’s market cap is 16% of Probiotec’s implied by the offer.</li>
</ul>


The Probiotec Ltd (PBP AU) IE considers Pyridam Farma (PYFA IJ)’s A$3.00 offer fair and reasonable as it is within its A$2.79-A$3.28 per share valuation range.
The scheme remains conditional on shareholders' (Probiotec and Pyridam), FIRB, and OJK approvals. Probiotec can also pay a permitted dividend of up to A$0.04 per share.
The gross spread of 4.9% (6.3% including dividends) reflects doubts about Pyridam’s funding credibility, as Pyridam’s market cap is 16% of Probiotec’s implied by the offer.


Probiotec (PBP AU): Scheme Vote on 29 May as Doubts on Pyridam’s Funding Linger

Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

SK Biopharmaceuticals   / Equity Bottom-Up

<ul>
<li>In 2Q23, Xcopri U.S. sales increased 57% YoY and 18% QoQ to KRW63.4B, marking the 13th consecutive quarter of growth since the company launched Xcopri in the U.S. in May’20.</li>
<li>Operating loss narrowed for the second consecutive quarters to KRW18.9B from KRW22.7B in 1Q23 and KRW40.1B in 2Q22. The company is on track to swing back to black in 4Q23.</li>
<li>
<a href="https://www.smartkarma.com/entities/sk-biopharmaceuticals-co-ltd" target="_blank" data-smartkarma-citation="entities:28966:1" rel="noopener">SK Biopharmaceuticals (326030 KS)</a> entered licensing agreement with <a href="https://www.smartkarma.com/entities/hikma-pharmaceuticals-plc" target="_blank" data-smartkarma-citation="entities:21969:1" rel="noopener">Hikma Pharmaceuticals (HIK LN)</a> to commercialize Xcopri in 16 countries in MENA, including Saudi Arabia, Egypt, and Algeria – three biggest epilepsy markets.</li>
</ul>


In 2Q23, Xcopri U.S. sales increased 57% YoY and 18% QoQ to KRW63.4B, marking the 13th consecutive quarter of growth since the company launched Xcopri in the U.S. in May’20.
Operating loss narrowed for the second consecutive quarters to KRW18.9B from KRW22.7B in 1Q23 and KRW40.1B in 2Q22. The company is on track to swing back to black in 4Q23.

SK Biopharmaceuticals (326030 KS) entered licensing agreement with Hikma Pharmaceuticals (HIK LN) to commercialize Xcopri in 16 countries in MENA, including Saudi Arabia, Egypt, and Algeria – three biggest epilepsy markets.


SK Biopharmaceuticals (326030 KS): Solid Growth in Xcopri US Sales in 2Q23; Operating Loss Narrowed

Index Rebal/Special Situations, Quiddity Advisors

Janaghan Jeyakumar, CFA

Index Rebal/Special Situations

<ul>
<li>In this insight, we take a look at the potential index changes for F100 and F250 in the run up to the September 2023 Rebalance.</li>
<li>I expect four changes for F100 and seven changes for F250 based on the latest available data.</li>
<li>However, with five more trading days left for the base date and with many names lurking close to the border, the rankings can still change.</li>
</ul>


In this insight, we take a look at the potential index changes for F100 and F250 in the run up to the September 2023 Rebalance.
I expect four changes for F100 and seven changes for F250 based on the latest available data.
However, with five more trading days left for the base date and with many names lurking close to the border, the rankings can still change.


Quiddity Leaderboard F100/​​​250 Sep 23: Several Changes Including Potential Surprises

<ul>
<li>In this insight, we take a look at the potential index changes for F100 and F250 in the run up to the September 2023 Rebalance.</li>
<li>I currently see one change for the F100 index and two separate changes for the F250 index.</li>
<li>There are several names lurking just outside the borders and could be involved in index changes in September 2023 if there are sharp price changes.</li>
</ul>


In this insight, we take a look at the potential index changes for F100 and F250 in the run up to the September 2023 Rebalance.
I currently see one change for the F100 index and two separate changes for the F250 index.
There are several names lurking just outside the borders and could be involved in index changes in September 2023 if there are sharp price changes.


Quiddity Leaderboard for F100/​​250 Sep 2023: One F100 Change and Two F250 Changes Likely

United Kingdom

Hikma Pharmaceuticals develops, manufactures, and markets a broad range of generic, branded, and in-licensed pharmaceutical products across North America, the Middle East and North Africa (MENA), and Europe. The company specializes in injectables, branded generics, and other non-injectable generic and specialty products for hospitals and retail markets. Hikma Pharmaceuticals was founded in 1978 in Amman, Jordan, and is headquartered in London, UK.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Hikma Pharmaceuticals (HIK LN)

Quiddity Leaderboard F100/F250 Mar26: Two High-Impact Intra-Review ADDs

We expect Henderson Far East Income (HFEL LN) to be the intra-review F250 replacement for Dowlais (DWL LN). Ashtead Group (AHT LN) is set to be...

Afridi Reyal

Probiotec (PBP AU): Scheme Vote on 29 May as Doubts on Pyridam’s Funding Linger

The spread reflects concerns about the credibility of Pyridam’s funding (which requires OJK approval) due to the stark disparities in market cap....

Arun George

SK Biopharmaceuticals (326030 KS): Solid Growth in Xcopri US Sales in 2Q23; Operating Loss Narrowed

In 2Q23, Xcopri U.S. sales grew 57% YoY and 18% QoQ to KRW63B, with operating loss narrowing. SK Biopharmaceuticals entered a licensing agreement...

Tina Banerjee

Quiddity Leaderboard F100/250 Sep 23: Several Changes Including Potential Surprises

Newly listed Cab Payments Holdings (CABP LN) and newly eligible Breedon Aggregates (BREE LN) and Ceres Power Holdings (CWR LN) could be added to...

Janaghan Jeyakumar, CFA

Quiddity Leaderboard for F100/250 Sep 2023: One F100 Change and Two F250 Changes Likely

Hikma Pharmaceuticals and Johnson Matthey could be F100 ADD and DEL respectively. Alfa Financial Software and 888 holdings could be F250 ADDs while...

Janaghan Jeyakumar, CFA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Quiddity Leaderboard F100/F250 Mar26: Two High-Impact Intra-Review ADDs

We expect Henderson Far East Income (HFEL LN) to be the intra-review F250 replacement for Dowlais (DWL LN). Ashtead Group (AHT LN) is set to be...

Afridi Reyal

Probiotec (PBP AU): Scheme Vote on 29 May as Doubts on Pyridam’s Funding Linger

The spread reflects concerns about the credibility of Pyridam’s funding (which requires OJK approval) due to the stark disparities in market cap....

Arun George

SK Biopharmaceuticals (326030 KS): Solid Growth in Xcopri US Sales in 2Q23; Operating Loss Narrowed

​In 2Q23, Xcopri U.S. sales grew 57% YoY and 18% QoQ to KRW63B, with operating loss narrowing. SK Biopharmaceuticals entered a licensing agreement...

Tina Banerjee

Quiddity Leaderboard F100/​​​250 Sep 23: Several Changes Including Potential Surprises

Newly listed Cab Payments Holdings (CABP LN) and newly eligible Breedon Aggregates (BREE LN) and Ceres Power Holdings (CWR LN) could be added to...

Janaghan Jeyakumar, CFA

Quiddity Leaderboard for F100/​​250 Sep 2023: One F100 Change and Two F250 Changes Likely

Hikma Pharmaceuticals and Johnson Matthey could be F100 ADD and DEL respectively. Alfa Financial Software and 888 holdings could be F250 ADDs while...

Janaghan Jeyakumar, CFA

In 2Q23, Xcopri U.S. sales grew 57% YoY and 18% QoQ to KRW63B, with operating loss narrowing. SK Biopharmaceuticals entered a licensing agreement...

Quiddity Leaderboard F100/250 Sep 23: Several Changes Including Potential Surprises

Quiddity Leaderboard for F100/250 Sep 2023: One F100 Change and Two F250 Changes Likely